| Title | State | Investigator/Sponsoring Organization |
|---|---|---|
| Study of Nivolumab or Nivolumab/BMS-986205 Alone or Combined With Intravesical BCG in Participants W... NCT ID: NCT03519256 State: Multi-State Trial Investigator/Sponsoring Organization: Bristol-Myers Squibb |
Multi-State Trial | Bristol-Myers Squibb |
| Study of Neoadjuvant and Adjuvant Nivolumab Plus NKTR-214, Versus Nivolumab Alone Versus Standard of... NCT ID: NCT04209114 State: Multi-State Trial Investigator/Sponsoring Organization: Bristol-Myers Squibb |
Multi-State Trial | Bristol-Myers Squibb |
| Study of Durvalumab (MEDI4736) Alone or in Combination With Oleclumab (MEDI9447) as Neoadjuvant Ther... NCT ID: NCT03773666 State: Multi-State Trial Investigator/Sponsoring Organization: Dana-Farber Cancer Institute |
Multi-State Trial | Dana-Farber Cancer Institute |
| Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanc... NCT ID: NCT03244384 State: Multi-State Trial Investigator/Sponsoring Organization: National Cancer Institute (NCI) |
Multi-State Trial | National Cancer Institute (NCI) |
| Modern ImmunotherApy in BCG-RelaPsing UroThelial Carcinoma of the BLADDER - (ADAPT-BLADDER) HCRN GU1... NCT ID: NCT03317158 State: Multi-State Trial Investigator/Sponsoring Organization: Noah Hahn, M.D. |
Multi-State Trial | Noah Hahn, M.D. |
| Study of Neoadjuvant Chemotherapy Alone Versus Neoadjuvant Chemotherapy Plus Nivolumab or Nivolumab ... NCT ID: NCT03661320 State: Multi-State Trial Investigator/Sponsoring Organization: Bristol-Myers Squibb |
Multi-State Trial | Bristol-Myers Squibb |
| Study of Ibrutinib Combination Therapy in Selected Advanced Urothelial or Bladder Cancer Tumors NCT ID: NCT02599324 State: Multi-State Trial Investigator/Sponsoring Organization: Pharmacyclics LLC. |
Multi-State Trial | Pharmacyclics LLC. |
| Study of Atezolizumab Plus PGV001, a Multipeptide Personalized Neoantigen Vaccine, in Patients With ... NCT ID: NCT03359239 State: New York Investigator/Sponsoring Organization: Matthew Galsky |
New York | Matthew Galsky |
| Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Erdafitinib Plus JNJ-6... NCT ID: NCT03473743 State: Multi-State Trial Investigator/Sponsoring Organization: Janssen Research & Development, LLC |
Multi-State Trial | Janssen Research & Development, LLC |
| Study of Adjuvant Nivolumab Versus Placebo in Subjects With High Risk Invasive Urothelial Carcinoma ... NCT ID: NCT02632409 State: Multi-State Trial Investigator/Sponsoring Organization: Bristol-Myers Squibb |
Multi-State Trial | Bristol-Myers Squibb |
| Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming With Intradermal BCG Be... NCT ID: NCT03091660 State: Multi-State Trial Investigator/Sponsoring Organization: Southwest Oncology Group |
Multi-State Trial | Southwest Oncology Group |
| IV Vitamin C With Chemotherapy for Cisplatin Ineligible Bladder Cancer Patients: A Forgotten Group NCT ID: NCT04046094 State: Multi-State Trial Investigator/Sponsoring Organization: University of Kansas Medical Center |
Multi-State Trial | University of Kansas Medical Center |
| Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Admin... NCT ID: NCT01968109 State: Multi-State Trial Investigator/Sponsoring Organization: Bristol-Myers Squibb |
Multi-State Trial | Bristol-Myers Squibb |
| Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene A... NCT ID: NCT03448718 State: Multi-State Trial Investigator/Sponsoring Organization: Matthew Galsky |
Multi-State Trial | Matthew Galsky |
| PORCH: A Registry of Prospective Outcomes of Radical Cystectomy With or Without Chemotherapy NCT ID: NCT01776138 State: North Carolina Investigator/Sponsoring Organization: UNC Lineberger Comprehensive Cancer Center |
North Carolina | UNC Lineberger Comprehensive Cancer Center |
| Afatinib Dimaleate in Treating Patients With Advanced Refractory Urothelial Cancer NCT ID: NCT02122172 State: Multi-State Trial Investigator/Sponsoring Organization: University of Chicago |
Multi-State Trial | University of Chicago |
| Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients With Muscle-Invasive Bladder Cance... NCT ID: NCT03609216 State: Multi-State Trial Investigator/Sponsoring Organization: Alliance for Clinical Trials in Oncology |
Multi-State Trial | Alliance for Clinical Trials in Oncology |
| First-Line Durvalumab in Combination With Standard of Care Chemotherapy and Durvalumab in Combinatio... NCT ID: NCT03682068 State: Multi-State Trial Investigator/Sponsoring Organization: AstraZeneca |
Multi-State Trial | AstraZeneca |
| Study of Olaparib (AZD2281) in Patients With Metastatic/Advanced Urothelial Carcinoma With DNA-Repai... NCT ID: NCT03375307 State: Multi-State Trial Investigator/Sponsoring Organization: National Cancer Institute (NCI) |
Multi-State Trial | National Cancer Institute (NCI) |
| Nivolumab in Combination With Intravesical BCG Versus Standard of Care BCG Alone in Participants Wit... NCT ID: NCT04149574 State: Multi-State Trial Investigator/Sponsoring Organization: Bristol-Myers Squibb |
Multi-State Trial | Bristol-Myers Squibb |
| Intra-corporal vs Extra-corporal Urinary Diversion After Robot Assisted Radical Cystectomy NCT ID: NCT03469362 State: Florida Investigator/Sponsoring Organization: University of Miami |
Florida | University of Miami |
| Defining the Genomic and Histologic Landscape of Primary and Metastatic Tumors With Divergent Kineti... NCT ID: NCT03291028 State: Pennsylvania Investigator/Sponsoring Organization: Fox Chase Cancer Center |
Pennsylvania | Fox Chase Cancer Center |
| Familial and Atypical Urothelial Cancer Registry NCT ID: NCT00902590 State: Multi-State Trial Investigator/Sponsoring Organization: Memorial Sloan Kettering Cancer Center |
Multi-State Trial | Memorial Sloan Kettering Cancer Center |
| Tremelimumab in Patients With Metastatic Urothelial Cancer Previously Treated With PD-1/PD-L1 Blocka... NCT ID: NCT03557918 State: Multi-State Trial Investigator/Sponsoring Organization: Matthew Galsky |
Multi-State Trial | Matthew Galsky |
| Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects With Advance... NCT ID: NCT03390504 State: Multi-State Trial Investigator/Sponsoring Organization: Janssen Research & Development, LLC |
Multi-State Trial | Janssen Research & Development, LLC |
| Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes NCT ID: NCT03757949 State: Multi-State Trial Investigator/Sponsoring Organization: Southwest Oncology Group |
Multi-State Trial | Southwest Oncology Group |
| Neoadjuvant Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer W... NCT ID: NCT03558087 State: Multi-State Trial Investigator/Sponsoring Organization: Matthew Galsky |
Multi-State Trial | Matthew Galsky |
| Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Perfo... NCT ID: NCT01224665 State: Multi-State Trial Investigator/Sponsoring Organization: Southwest Oncology Group |
Multi-State Trial | Southwest Oncology Group |
| CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer NCT ID: NCT03933826 State: Multi-State Trial Investigator/Sponsoring Organization: University of Washington |
Multi-State Trial | University of Washington |
| GU-114: Overcoming Checkpoint Inhibitor Resistance With Epigenetic Therapy in Urothelial Cancer NCT ID: NCT03179943 State: Multi-State Trial Investigator/Sponsoring Organization: Fox Chase Cancer Center |
Multi-State Trial | Fox Chase Cancer Center |
| Trial of Preventive Mesh Placement at the Time of Radical Cystectomy to Reduce the Chances of Develo... NCT ID: NCT02908061 State: Multi-State Trial Investigator/Sponsoring Organization: Memorial Sloan Kettering Cancer Center |
Multi-State Trial | Memorial Sloan Kettering Cancer Center |
| Trial of Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cispl... NCT ID: NCT03451331 State: Multi-State Trial Investigator/Sponsoring Organization: Matthew Galsky |
Multi-State Trial | Matthew Galsky |
| Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillu... NCT ID: NCT04172675 State: Multi-State Trial Investigator/Sponsoring Organization: Janssen Research & Development, LLC |
Multi-State Trial | Janssen Research & Development, LLC |
| Atezolizumab and Bevacizumab in Cisplatin-ineligible Patients With Advanced/Unresectable Urothelial ... NCT ID: NCT03272217 State: Multi-State Trial Investigator/Sponsoring Organization: Arjun Balar, MD |
Multi-State Trial | Arjun Balar, MD |
| Trial of MK3475 in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy as... NCT ID: NCT02621151 State: Multi-State Trial Investigator/Sponsoring Organization: NYU Langone Health |
Multi-State Trial | NYU Langone Health |
| Study of Gemcitabine and Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Prior to Radical Cystec... NCT ID: NCT02690558 State: Multi-State Trial Investigator/Sponsoring Organization: UNC Lineberger Comprehensive Cancer Center |
Multi-State Trial | UNC Lineberger Comprehensive Cancer Center |
| Study of Nivolumab Combined With Ipilimumab, or With Standard of Care Chemotherapy, Versus Standard ... NCT ID: NCT03036098 State: Multi-State Trial Investigator/Sponsoring Organization: Bristol-Myers Squibb |
Multi-State Trial | Bristol-Myers Squibb |
| Pembrolizumab and aMVAC Chemotherapy as Neoadjuvant Therapy in Non-Urothelial Histology Muscle-Invas... NCT ID: NCT04383743 State: Washington Investigator/Sponsoring Organization: University of Washington |
Washington | University of Washington |
| Neoadjuvant Infigratinib, an Inhibitor of FGFR, in Upper Tract Urothelial Carcinoma NCT ID: NCT04228042 State: Texas Investigator/Sponsoring Organization: M.D. Anderson Cancer Center |
Texas | M.D. Anderson Cancer Center |
| A Phase II Study of TAS-102 in Metastatic Platinum and Checkpoint Inhibitor-resistant Bladder Cancer NCT ID: NCT03762161 State: Multi-State Trial Investigator/Sponsoring Organization: Rahul Parikh |
Multi-State Trial | Rahul Parikh |
| Addressing Barriers to Palliative Care Use in Bladder Cancer Through Better Understanding of Knowled... NCT ID: NCT04598724 State: Florida Investigator/Sponsoring Organization: H. Lee Moffitt Cancer Center and Research Institute |
Florida | H. Lee Moffitt Cancer Center and Research Institute |
| UGN-102 With or Without TURBT in Patients With Low Grade Intermediate Risk Non-Muscle-Invasive Bladd... NCT ID: NCT04688931 State: Multi-State Trial Investigator/Sponsoring Organization: UroGen Pharma Ltd. |
Multi-State Trial | UroGen Pharma Ltd. |
| Title | State | Investigator/Sponsoring Organization |
|---|---|---|
| Study of TAS-120 in Patients With Advanced Solid Tumors Harboring FGF/FGFR Aberrations NCT ID: NCT02052778 State: Multi-State Trial Investigator/Sponsoring Organization: Taiho Oncology, Inc. |
Multi-State Trial | Taiho Oncology, Inc. |
| Combination of Rogaratinib and Copanlisib in Patients With FGFR-positive, Locally Advanced or Metas... NCT ID: NCT03517956 State: Multi-State Trial Investigator/Sponsoring Organization: Bayer |
Multi-State Trial | Bayer |
| STUDY TO EVALUATE SAFETY AND EFFICACY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH CHEMOTHERAPY WIT... NCT ID: NCT03317496 State: Multi-State Trial Investigator/Sponsoring Organization: Pfizer |
Multi-State Trial | Pfizer |
| STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ESCALATING DOSES OF PF-06940... NCT ID: NCT04152018 State: Multi-State Trial Investigator/Sponsoring Organization: Pfizer |
Multi-State Trial | Pfizer |
| Study of Nivolumab or Nivolumab/BMS-986205 Alone or Combined With Intravesical BCG in Participants W... NCT ID: NCT03519256 State: Multi-State Trial Investigator/Sponsoring Organization: Bristol-Myers Squibb |
Multi-State Trial | Bristol-Myers Squibb |
| GSK3359609 in Combination With Tremelimumab in Participants With Selected, Advanced Solid Tumors NCT ID: NCT03693612 State: Multi-State Trial Investigator/Sponsoring Organization: GlaxoSmithKline |
Multi-State Trial | GlaxoSmithKline |
| Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15... NCT ID: NCT04068896 State: Multi-State Trial Investigator/Sponsoring Organization: NGM Biopharmaceuticals, Inc |
Multi-State Trial | NGM Biopharmaceuticals, Inc |
| Study of NIR178 in Combination With PDR001 in Patients With Selected Advanced Bladder Cancer NCT ID: NCT03207867 State: Multi-State Trial Investigator/Sponsoring Organization: Novartis Pharmaceuticals |
Multi-State Trial | Novartis Pharmaceuticals |
| Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity o... NCT ID: NCT04143711 State: Multi-State Trial Investigator/Sponsoring Organization: Dragonfly Therapeutics |
Multi-State Trial | Dragonfly Therapeutics |
| Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients With BCG-Unrespons... NCT ID: NCT04164082 State: Multi-State Trial Investigator/Sponsoring Organization: National Cancer Institute (NCI) |
Multi-State Trial | National Cancer Institute (NCI) |
| Study of an Immunotherapeutic Treatment, DPX-Survivac in Combination With Low Dose Cyclophosphamide... NCT ID: NCT03836352 State: Multi-State Trial Investigator/Sponsoring Organization: ImmunoVaccine Technologies, Inc. (IMV Inc.) |
Multi-State Trial | ImmunoVaccine Technologies, Inc. (IMV Inc.) |
| Study to Evaluate the Safety and Preliminary Efficacy of SO-C101 as Monotherapy and in Combination W... NCT ID: NCT04234113 State: Multi-State Trial Investigator/Sponsoring Organization: Sotio a.s. |
Multi-State Trial | Sotio a.s. |
| Study of Enfortumab Vedotin (ASG-22CE) as Monotherapy or in Combination With Other Anticancer Therap... NCT ID: NCT03288545 State: Multi-State Trial Investigator/Sponsoring Organization: Astellas Pharma Global Development, Inc. |
Multi-State Trial | Astellas Pharma Global Development, Inc. |
| Study of CPX-POM in Patients With Advanced Solid Tumors. The First Part of the Study is Completed an... NCT ID: NCT03348514 State: Multi-State Trial Investigator/Sponsoring Organization: CicloMed LLC |
Multi-State Trial | CicloMed LLC |
| Study of Neoadjuvant Nivolumab With and Without Urelumab in Patients With Cisplatin-Ineligible Muscl... NCT ID: NCT02845323 State: Multi-State Trial Investigator/Sponsoring Organization: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Multi-State Trial | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
| Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination With Pemb... NCT ID: NCT03849469 State: Multi-State Trial Investigator/Sponsoring Organization: Xencor, Inc. |
Multi-State Trial | Xencor, Inc. |
| Leukocyte Telomere Length: Diet and Exercise Trial NCT ID: NCT03286699 State: Pennsylvania Investigator/Sponsoring Organization: University of Pittsburgh |
Pennsylvania | University of Pittsburgh |
| Safety And Preliminary Efficacy Study of MRx0518 In Combination With Pembrolizumab In Patients With ... NCT ID: NCT03637803 State: Multi-State Trial Investigator/Sponsoring Organization: 4D pharma plc |
Multi-State Trial | 4D pharma plc |
| Study Evaluating Safety and Efficacy of TAR-200 in Subjects With Muscle-Invasive Urothelial Carcinom... NCT ID: NCT03404791 State: Multi-State Trial Investigator/Sponsoring Organization: Taris Biomedical LLC |
Multi-State Trial | Taris Biomedical LLC |
| Study to Evaluate the Safety and Tolerability of XmAb®20717 in Subjects With Selected Advanced Solid... NCT ID: NCT03517488 State: Multi-State Trial Investigator/Sponsoring Organization: Xencor, Inc. |
Multi-State Trial | Xencor, Inc. |
| Study of MK-3475 in Combination With BCG for Patients With High Risk Superficial Bladder Cancer NCT ID: NCT02324582 State: Multi-State Trial Investigator/Sponsoring Organization: Southern Illinois University |
Multi-State Trial | Southern Illinois University |
| Study of Sitravatinib in Combination With Nivolumab in Patients With Advanced or Metastatic Urotheli... NCT ID: NCT03606174 State: Multi-State Trial Investigator/Sponsoring Organization: Mirati Therapeutics Inc. |
Multi-State Trial | Mirati Therapeutics Inc. |
| Study of Celecoxib Combined With Gemcitabine and Cisplatin for Neoadjuvant Treatment of Localized, M... NCT ID: NCT02885974 State: Multi-State Trial Investigator/Sponsoring Organization: Baylor College of Medicine |
Multi-State Trial | Baylor College of Medicine |
| Study of the Combination of Durvalumab (MEDI4736) and Vicinium (Oportuzumab Monatox, VB4-845) in Sub... NCT ID: NCT03258593 State: Maryland Investigator/Sponsoring Organization: National Cancer Institute (NCI) |
Maryland | National Cancer Institute (NCI) |
| Recovery Support for Bladder Cancer Patients and Caregivers: A Multimodal Approach NCT ID: NCT04055311 State: Multi-State Trial Investigator/Sponsoring Organization: Northwell Health |
Multi-State Trial | Northwell Health |
| FAST: Feasibility Trial of Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Ur... NCT ID: NCT03287050 State: Michigan Investigator/Sponsoring Organization: University of Michigan Rogel Cancer Center |
Michigan | University of Michigan Rogel Cancer Center |
| Intravesical VAX014 for Instillation in Subjects With Non-Muscle Invasive Bladder Cancer (NMIBC) NCT ID: NCT03854721 State: Multi-State Trial Investigator/Sponsoring Organization: Vaxiion Therapeutics |
Multi-State Trial | Vaxiion Therapeutics |
| Study of Neoadjuvant and Adjuvant Nivolumab Plus NKTR-214, Versus Nivolumab Alone Versus Standard of... NCT ID: NCT04209114 State: Multi-State Trial Investigator/Sponsoring Organization: Bristol-Myers Squibb |
Multi-State Trial | Bristol-Myers Squibb |
| Study of Durvalumab (MEDI4736) Alone or in Combination With Oleclumab (MEDI9447) as Neoadjuvant Ther... NCT ID: NCT03773666 State: Multi-State Trial Investigator/Sponsoring Organization: Dana-Farber Cancer Institute |
Multi-State Trial | Dana-Farber Cancer Institute |
| Neoadjuvant Intravesical NIS Measles Virus (MV-NIS) in Patients Undergoing Cystectomy for Urothelial... NCT ID: NCT03171493 State: Multi-State Trial Investigator/Sponsoring Organization: Vyriad, Inc. |
Multi-State Trial | Vyriad, Inc. |
| Study of the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Gu... NCT ID: NCT03711032 State: Multi-State Trial Investigator/Sponsoring Organization: Merck Sharp & Dohme Corp. |
Multi-State Trial | Merck Sharp & Dohme Corp. |
| Study of 18Fluorine-Fluciclovine Positron Emission Tomography/Computed Tomography for Staging Muscle... NCT ID: NCT04018053 State: Massachusetts Investigator/Sponsoring Organization: Dana-Farber Cancer Institute |
Massachusetts | Dana-Farber Cancer Institute |
| Study of Intravesical MK-3475 and Bacillus Calmette-Guerin (BCG) in Subjects With High Risk and BCG-... NCT ID: NCT02808143 State: Illinois Investigator/Sponsoring Organization: Northwestern University |
Illinois | Northwestern University |
| Study of TAR-200 in Combination With Nivolumab (OPDIVO) in Subjects With Muscle-Invasive Urothelial ... NCT ID: NCT03518320 State: Multi-State Trial Investigator/Sponsoring Organization: Taris Biomedical LLC |
Multi-State Trial | Taris Biomedical LLC |
| Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanc... NCT ID: NCT03244384 State: Multi-State Trial Investigator/Sponsoring Organization: National Cancer Institute (NCI) |
Multi-State Trial | National Cancer Institute (NCI) |
| Study of Cystectomy Plus Perioperative Pembrolizumab Versus Cystectomy Alone in Cisplatin-ineligible... NCT ID: NCT03924895 State: Multi-State Trial Investigator/Sponsoring Organization: Merck Sharp & Dohme Corp. |
Multi-State Trial | Merck Sharp & Dohme Corp. |
| Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Blad... NCT ID: NCT03775265 State: Multi-State Trial Investigator/Sponsoring Organization: National Cancer Institute (NCI) |
Multi-State Trial | National Cancer Institute (NCI) |
| Study of Albumin-bound Rapamycin Nanoparticles (Nab-rapamycin, ABI-009) in the Treatment of BCG Refr... NCT ID: NCT02009332 State: Multi-State Trial Investigator/Sponsoring Organization: Aadi, LLC |
Multi-State Trial | Aadi, LLC |
| Evaluating the Efficacy and Safety of UGN-101 (Mitomycin Gel) for Instillation on Ablation of Upper ... NCT ID: NCT04006691 State: Multi-State Trial Investigator/Sponsoring Organization: UroGen Pharma Ltd. |
Multi-State Trial | UroGen Pharma Ltd. |
| Study of Trastuzumab Deruxtecan (DS-8201a), an Anti-Human Epidermal Growth Factor Receptor-2 (HER2)-... NCT ID: NCT03523572 State: Multi-State Trial Investigator/Sponsoring Organization: Daiichi Sankyo, Inc. |
Multi-State Trial | Daiichi Sankyo, Inc. |
| Study of INCAGN02385 in Participants With Select Advanced Malignancies NCT ID: NCT03538028 State: Multi-State Trial Investigator/Sponsoring Organization: Incyte Biosciences International Sàrl |
Multi-State Trial | Incyte Biosciences International Sàrl |
| Study of CK-301 Administered Intravenously as a Single Agent to Subjects With Advanced Cancers NCT ID: NCT03212404 State: Multi-State Trial Investigator/Sponsoring Organization: Checkpoint Therapeutics, Inc. |
Multi-State Trial | Checkpoint Therapeutics, Inc. |
| Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinati... NCT ID: NCT03872947 State: Multi-State Trial Investigator/Sponsoring Organization: Toray Industries, Inc |
Multi-State Trial | Toray Industries, Inc |
| Phase Ib Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patie... NCT ID: NCT02869217 State: Ontario Investigator/Sponsoring Organization: University Health Network, Toronto |
Ontario | University Health Network, Toronto |
| A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With ... NCT ID: NCT02138734 State: Multi-State Trial Investigator/Sponsoring Organization: ImmunityBio, Inc. |
Multi-State Trial | ImmunityBio, Inc. |
| Combination of Avelumab and Taxane Based Chemotherapy in Platinum Refractory or Ineligible Metastati... NCT ID: NCT03575013 State: Iowa Investigator/Sponsoring Organization: Rohan Garje |
Iowa | Rohan Garje |
| Study to Evaluate Safety, Pharmacodynamics and Efficacy of Pembrolizumab (MK-3475) in Combination Wi... NCT ID: NCT02619253 State: Multi-State Trial Investigator/Sponsoring Organization: Roberto Pili |
Multi-State Trial | Roberto Pili |
| Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 (Tremelimumab) in Pa... NCT ID: NCT02812420 State: Texas Investigator/Sponsoring Organization: M.D. Anderson Cancer Center |
Texas | M.D. Anderson Cancer Center |
| Study of the Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination With Atez... NCT ID: NCT03289962 State: Multi-State Trial Investigator/Sponsoring Organization: Genentech, Inc. |
Multi-State Trial | Genentech, Inc. |
| Study of the Non-receptor Kinase Inhibitor Bosutinib in Combination With Pemetrexed in Patients With... NCT ID: NCT03023319 State: Georgia Investigator/Sponsoring Organization: Nagla Abdel Karim |
Georgia | Nagla Abdel Karim |
| Study of CPI-444 as Single Agent and in Combination With Atezolizumab in Patients With Selected Incu... NCT ID: NCT02655822 State: Multi-State Trial Investigator/Sponsoring Organization: Corvus Pharmaceuticals, Inc. |
Multi-State Trial | Corvus Pharmaceuticals, Inc. |
| Modern ImmunotherApy in BCG-RelaPsing UroThelial Carcinoma of the BLADDER - (ADAPT-BLADDER) HCRN GU1... NCT ID: NCT03317158 State: Multi-State Trial Investigator/Sponsoring Organization: Noah Hahn, M.D. |
Multi-State Trial | Noah Hahn, M.D. |
| Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuva... NCT ID: NCT03633110 State: Multi-State Trial Investigator/Sponsoring Organization: Genocea Biosciences, Inc. |
Multi-State Trial | Genocea Biosciences, Inc. |
| Study of an Agonist Redirected Checkpoint Fusion Protein, SL-279252 (PD1-Fc-OX40L), in Subjects With... NCT ID: NCT03894618 State: Multi-State Trial Investigator/Sponsoring Organization: Shattuck Labs, Inc. |
Multi-State Trial | Shattuck Labs, Inc. |
| Study of Neoadjuvant Chemotherapy Alone Versus Neoadjuvant Chemotherapy Plus Nivolumab or Nivolumab ... NCT ID: NCT03661320 State: Multi-State Trial Investigator/Sponsoring Organization: Bristol-Myers Squibb |
Multi-State Trial | Bristol-Myers Squibb |
| Abemaciclib Followed by Radical Cystectomy in Patients With Platinum-ineligible Urothelial Carcinoma... NCT ID: NCT03837821 State: New York Investigator/Sponsoring Organization: Weill Medical College of Cornell University |
New York | Weill Medical College of Cornell University |
| Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-based Treatment Combinations in P... NCT ID: NCT03869190 State: Multi-State Trial Investigator/Sponsoring Organization: Hoffmann-La Roche |
Multi-State Trial | Hoffmann-La Roche |
| A Phase 1, Open-Label, Dose Escalation Study of PRS-343 in Patients With HER2-Positive Advanced or M... NCT ID: NCT03330561 State: Multi-State Trial Investigator/Sponsoring Organization: Pieris Pharmaceuticals, Inc. |
Multi-State Trial | Pieris Pharmaceuticals, Inc. |
| A Phase 1/2, Open-label, Multicenter Study of the Combination of NKTR-214 and Nivolumab or the Combi... NCT ID: NCT02983045 State: Multi-State Trial Investigator/Sponsoring Organization: Nektar Therapeutics |
Multi-State Trial | Nektar Therapeutics |
| Study of Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Maligna... NCT ID: NCT03590054 State: California Investigator/Sponsoring Organization: Rahul Aggarwal |
California | Rahul Aggarwal |
| An Open-label Multi-cohort Phase 1b/2 Study of Derazantinib and Atezolizumab in Patients With Urothe... NCT ID: NCT04045613 State: Multi-State Trial Investigator/Sponsoring Organization: Basilea Pharmaceutica |
Multi-State Trial | Basilea Pharmaceutica |
| Study of PRS-343 in Combination With Atezolizumab in Patients With HER2-Positive Advanced or Metasta... NCT ID: NCT03650348 State: Multi-State Trial Investigator/Sponsoring Organization: Pieris Pharmaceuticals, Inc. |
Multi-State Trial | Pieris Pharmaceuticals, Inc. |
| SEASTAR: A Phase 1b/2, Open-label, Parallel Arm Study to Assess the Safety, Tolerability, Pharmacoki... NCT ID: NCT03992131 State: Multi-State Trial Investigator/Sponsoring Organization: Clovis Oncology, Inc. |
Multi-State Trial | Clovis Oncology, Inc. |
| Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab NCT ID: NCT03409458 State: Multi-State Trial Investigator/Sponsoring Organization: Phosplatin Therapeutics |
Multi-State Trial | Phosplatin Therapeutics |
| Study of WST11 Phototherapy for Upper Tract Urothelial Carcinoma NCT ID: NCT03617003 State: New York Investigator/Sponsoring Organization: Memorial Sloan Kettering Cancer Center |
New York | Memorial Sloan Kettering Cancer Center |
| Study of INBRX-105 in Patients With Locally Advanced or Metastatic Solid Tumors, Hodgkin or Non-Hodg... NCT ID: NCT03809624 State: Multi-State Trial Investigator/Sponsoring Organization: Inhibrx, Inc. |
Multi-State Trial | Inhibrx, Inc. |
| The IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors: A Phase 1b Study to ... NCT ID: NCT03758781 State: Florida Investigator/Sponsoring Organization: H. Lee Moffitt Cancer Center and Research Institute |
Florida | H. Lee Moffitt Cancer Center and Research Institute |
| Study of INCAGN02390 in Participants With Select Advanced Malignancies NCT ID: NCT03652077 State: Multi-State Trial Investigator/Sponsoring Organization: Incyte Corporation |
Multi-State Trial | Incyte Corporation |
| Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Camidanlumab... NCT ID: NCT03621982 State: Multi-State Trial Investigator/Sponsoring Organization: ADC Therapeutics S.A. |
Multi-State Trial | ADC Therapeutics S.A. |
| Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Pati... NCT ID: NCT01552434 State: Texas Investigator/Sponsoring Organization: M.D. Anderson Cancer Center |
Texas | M.D. Anderson Cancer Center |
| Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi... NCT ID: NCT02496208 State: Multi-State Trial Investigator/Sponsoring Organization: National Cancer Institute (NCI) |
Multi-State Trial | National Cancer Institute (NCI) |
| An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects W... NCT ID: NCT03474107 State: Multi-State Trial Investigator/Sponsoring Organization: Astellas Pharma Global Development, Inc. |
Multi-State Trial | Astellas Pharma Global Development, Inc. |
| NKTR-214 in Combination With Anti-PD-1 (Pembrolizumab) or Anti-PD-L1 (Atezolizumab) in Patients With... NCT ID: NCT03138889 State: Multi-State Trial Investigator/Sponsoring Organization: Nektar Therapeutics |
Multi-State Trial | Nektar Therapeutics |
| Study of Ibrutinib Combination Therapy in Selected Advanced Urothelial or Bladder Cancer Tumors NCT ID: NCT02599324 State: Multi-State Trial Investigator/Sponsoring Organization: Pharmacyclics LLC. |
Multi-State Trial | Pharmacyclics LLC. |
| Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered MAGE-A4ᶜ¹º... NCT ID: NCT03132922 State: Multi-State Trial Investigator/Sponsoring Organization: Adaptimmune |
Multi-State Trial | Adaptimmune |
| A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participant... NCT ID: NCT03629756 State: Multi-State Trial Investigator/Sponsoring Organization: Arcus Biosciences, Inc. |
Multi-State Trial | Arcus Biosciences, Inc. |
| Targeting a Genomic Biomarker for PET Imaging and Staging of Urothelial Cancer: A Preliminary Evalua... NCT ID: NCT03039413 State: Pennsylvania Investigator/Sponsoring Organization: Sidney Kimmel Cancer Center at Thomas Jefferson University |
Pennsylvania | Sidney Kimmel Cancer Center at Thomas Jefferson University |
| Safety and Tolerability of Genetically Engineered MAGE-A10ᶜ⁷⁹⁶T in HLA-A2+ Subjects With MAGE-A10 Po... NCT ID: NCT02989064 State: Multi-State Trial Investigator/Sponsoring Organization: Adaptimmune |
Multi-State Trial | Adaptimmune |
| Study of ADXS NEO Expressing Personalized Tumor Antigens, Alone and in Combination With Pembrolizuma... NCT ID: NCT03265080 State: Multi-State Trial Investigator/Sponsoring Organization: Advaxis, Inc. |
Multi-State Trial | Advaxis, Inc. |
| Study To Evaluate The Humanized Anti-CD73 Antibody, CPI-006, As A Single Agent, In Combination With ... NCT ID: NCT03454451 State: Multi-State Trial Investigator/Sponsoring Organization: Corvus Pharmaceuticals, Inc. |
Multi-State Trial | Corvus Pharmaceuticals, Inc. |
| A Phase 1 Study to Evaluate the Safety and Tolerability of AB154 Monotherapy and Combination Therapy... NCT ID: NCT03628677 State: Multi-State Trial Investigator/Sponsoring Organization: Arcus Biosciences, Inc. |
Multi-State Trial | Arcus Biosciences, Inc. |
| Trial Evaluating the Safety and Tolerability of NanoDoce® Injection and Intravesical Instillation in... NCT ID: NCT03636256 State: Multi-State Trial Investigator/Sponsoring Organization: NanOlogy, LLC |
Multi-State Trial | NanOlogy, LLC |
| Study of Atezolizumab Plus PGV001, a Multipeptide Personalized Neoantigen Vaccine, in Patients With ... NCT ID: NCT03359239 State: New York Investigator/Sponsoring Organization: Matthew Galsky |
New York | Matthew Galsky |
| Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Erdafitinib Plus JNJ-6... NCT ID: NCT03473743 State: Multi-State Trial Investigator/Sponsoring Organization: Janssen Research & Development, LLC |
Multi-State Trial | Janssen Research & Development, LLC |
| Study of Adjuvant Nivolumab Versus Placebo in Subjects With High Risk Invasive Urothelial Carcinoma ... NCT ID: NCT02632409 State: Multi-State Trial Investigator/Sponsoring Organization: Bristol-Myers Squibb |
Multi-State Trial | Bristol-Myers Squibb |
| Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab as First-line Treatment in Cispla... NCT ID: NCT03473756 State: Multi-State Trial Investigator/Sponsoring Organization: Bayer |
Multi-State Trial | Bayer |
| Study of GRT-C901/GRT-R902, a Neoantigen Cancer Vaccine, in Combination With Immune Checkpoint Block... NCT ID: NCT03639714 State: Multi-State Trial Investigator/Sponsoring Organization: Gritstone Oncology, Inc. |
Multi-State Trial | Gritstone Oncology, Inc. |
| Avelumab in Non-metastatic Muscle Invasive Bladder Cancer (BL-AIR: Bladder Cancer-Avelumab for Invas... NCT ID: NCT03498196 State: Multi-State Trial Investigator/Sponsoring Organization: Baylor College of Medicine |
Multi-State Trial | Baylor College of Medicine |
| Trial of L-NMMA in Combination With Pembrolizumab in Patients With Melanoma, Non-Small Cell Lung Can... NCT ID: NCT03236935 State: Texas Investigator/Sponsoring Organization: Jorge G. Darcourt |
Texas | Jorge G. Darcourt |
| Pembrolizumab (MK-3475) With Platinum-Based Chemotherapy in Small Cell%2FNeuroendocrine Cancers of U... NCT ID: NCT03582475 State: California Investigator/Sponsoring Organization: Jonsson Comprehensive Cancer Center |
California | Jonsson Comprehensive Cancer Center |
| MK3475 + Docetaxel or Gemcitabine in Platinum Pre-treated Urothelial Cancer NCT ID: NCT02437370 State: California Investigator/Sponsoring Organization: University of California, Davis |
California | University of California, Davis |
| Study of TPST-1120 as a Single Agent or in Combination With Systemic Anti-Cancer Therapies in Subjec... NCT ID: NCT03829436 State: Multi-State Trial Investigator/Sponsoring Organization: Tempest Therapeutics |
Multi-State Trial | Tempest Therapeutics |
| Study of Palbociclib in Combination With Cisplatin or Carboplatin in Advanced Solid Malignancies NCT ID: NCT02897375 State: Georgia Investigator/Sponsoring Organization: Emory University |
Georgia | Emory University |
| Study to Determine the Efficacy and Safety of Durvalumab in Combination With Gemcitabine+Cisplatin f... NCT ID: NCT03732677 State: Multi-State Trial Investigator/Sponsoring Organization: AstraZeneca |
Multi-State Trial | AstraZeneca |
| Study of PRN1371, a FGFR 1-4 Kinase Inhibitor, in Adult Patients With Advanced Solid Tumors, Followe... NCT ID: NCT02608125 State: Multi-State Trial Investigator/Sponsoring Organization: Principia Biopharma Inc. |
Multi-State Trial | Principia Biopharma Inc. |
| Study of Daratumumab (CD38 Antagonist) in Patients With Metastatic Renal Cell Carcinoma or Muscle In... NCT ID: NCT03473730 State: Texas Investigator/Sponsoring Organization: M.D. Anderson Cancer Center |
Texas | M.D. Anderson Cancer Center |
| Study To Assess Safety And Efficacy Of ADP-A2M4CD8 In HLA-A2+ Subjects With MAGE-A4 Positive Tumors NCT ID: NCT04044859 State: Multi-State Trial Investigator/Sponsoring Organization: Adaptimmune |
Multi-State Trial | Adaptimmune |
| FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced ... NCT ID: NCT03841110 State: Multi-State Trial Investigator/Sponsoring Organization: Fate Therapeutics |
Multi-State Trial | Fate Therapeutics |
| Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming With Intradermal BCG Be... NCT ID: NCT03091660 State: Multi-State Trial Investigator/Sponsoring Organization: Southwest Oncology Group |
Multi-State Trial | Southwest Oncology Group |
| Study Evaluating the Safety, Pharmacology and Preliminary Activity of MM-310 in Patients With Solid ... NCT ID: NCT03076372 State: Multi-State Trial Investigator/Sponsoring Organization: Merrimack Pharmaceuticals |
Multi-State Trial | Merrimack Pharmaceuticals |
| Study to Evaluate the Safety and Tolerability of XmAb®23104 in Subjects With Selected Advanced Solid... NCT ID: NCT03752398 State: Multi-State Trial Investigator/Sponsoring Organization: Xencor, Inc. |
Multi-State Trial | Xencor, Inc. |
| Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies NCT ID: NCT03329950 State: Multi-State Trial Investigator/Sponsoring Organization: Celldex Therapeutics |
Multi-State Trial | Celldex Therapeutics |
| Tranexamic Acid During Cystectomy Trial (TACT) NCT ID: NCT01869413 State: Multi-State Trial Investigator/Sponsoring Organization: Ottawa Hospital Research Institute |
Multi-State Trial | Ottawa Hospital Research Institute |
| Study of Intra-tumoral Injections in Metastatic Urological Cancers NCT ID: NCT03071328 State: North Carolina Investigator/Sponsoring Organization: Duke University |
North Carolina | Duke University |
| STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ESCALATING DOSES OF PF-06939... NCT ID: NCT03854227 State: Multi-State Trial Investigator/Sponsoring Organization: Pfizer |
Multi-State Trial | Pfizer |
| Study of Gemcitabine and Cisplatin With Atezolizumab (MPDL3280A) in Patients With Metastatic and Mus... NCT ID: NCT02989584 State: Multi-State Trial Investigator/Sponsoring Organization: Memorial Sloan Kettering Cancer Center |
Multi-State Trial | Memorial Sloan Kettering Cancer Center |
| IV Vitamin C With Chemotherapy for Cisplatin Ineligible Bladder Cancer Patients: A Forgotten Group NCT ID: NCT04046094 State: Multi-State Trial Investigator/Sponsoring Organization: University of Kansas Medical Center |
Multi-State Trial | University of Kansas Medical Center |
| Study of Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder Ca... NCT ID: NCT03892642 State: Oklahoma Investigator/Sponsoring Organization: University of Oklahoma |
Oklahoma | University of Oklahoma |
| Study of Intravesical TSD-001 for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Canc... NCT ID: NCT03081858 State: Multi-State Trial Investigator/Sponsoring Organization: Lipac Oncology LLC |
Multi-State Trial | Lipac Oncology LLC |
| Study of Neoadjuvant sEphB4-HSA in Patients With Stage ll Bladder Cancer NCT ID: NCT02767921 State: California Investigator/Sponsoring Organization: University of Southern California |
California | University of Southern California |
| Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor IN... NCT ID: NCT02903914 State: Multi-State Trial Investigator/Sponsoring Organization: Incyte Corporation |
Multi-State Trial | Incyte Corporation |
| Neutron Radiotherapy With Concurrent Checkpoint Inhibitor Immunotherapy (Pembrolizumab) in Patients ... NCT ID: NCT03486197 State: Washington Investigator/Sponsoring Organization: University of Washington |
Washington | University of Washington |
| QUILT-3.055: Study of ALT-803 in Combination With PD-1/PD-L1 Checkpoint Inhibitor in Patients Who Ha... NCT ID: NCT03228667 State: Multi-State Trial Investigator/Sponsoring Organization: Altor BioScience |
Multi-State Trial | Altor BioScience |
| Exploring Relevant Immune-based Biomarkers and Circulating Tumor Cells During Treatment With Immune ... NCT ID: NCT02978118 State: North Carolina Investigator/Sponsoring Organization: Duke University |
North Carolina | Duke University |
| Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Admin... NCT ID: NCT01968109 State: Multi-State Trial Investigator/Sponsoring Organization: Bristol-Myers Squibb |
Multi-State Trial | Bristol-Myers Squibb |
| Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene A... NCT ID: NCT03448718 State: Multi-State Trial Investigator/Sponsoring Organization: Matthew Galsky |
Multi-State Trial | Matthew Galsky |
| Study of QUILT-3.032 (CA ALT-803-01-16): A Multicenter Clinical Trial of Intravesical Bacillus Calme... NCT ID: NCT04142359 State: Multi-State Trial Investigator/Sponsoring Organization: Altor BioScience |
Multi-State Trial | Altor BioScience |
| Study of Bempegaldesleukin (NKTR-214) in Combination With Nivolumab in Cisplatin Ineligible, Locally... NCT ID: NCT03785925 State: Multi-State Trial Investigator/Sponsoring Organization: Nektar Therapeutics |
Multi-State Trial | Nektar Therapeutics |
| Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT5528 in Patients With ... NCT ID: NCT04180371 State: Multi-State Trial Investigator/Sponsoring Organization: Bicycle Tx Limited |
Multi-State Trial | Bicycle Tx Limited |
| A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination Wit... NCT ID: NCT03126110 State: Multi-State Trial Investigator/Sponsoring Organization: Incyte Biosciences International Sàrl |
Multi-State Trial | Incyte Biosciences International Sàrl |
| PORCH: A Registry of Prospective Outcomes of Radical Cystectomy With or Without Chemotherapy NCT ID: NCT01776138 State: North Carolina Investigator/Sponsoring Organization: UNC Lineberger Comprehensive Cancer Center |
North Carolina | UNC Lineberger Comprehensive Cancer Center |
| Study of the Anti-PD-L1 Antibody MPDL3280A in Subjects With Non-metastatic Transitional Cell Carcino... NCT ID: NCT02451423 State: Multi-State Trial Investigator/Sponsoring Organization: Lawrence Fong |
Multi-State Trial | Lawrence Fong |
| Study of Atezolizumab (MPDL3280A) Plus Recombinant Human IL-7 (CYT107) in Patients With Locally Adva... NCT ID: NCT03513952 State: Multi-State Trial Investigator/Sponsoring Organization: National Cancer Institute (NCI) |
Multi-State Trial | National Cancer Institute (NCI) |
| The PIONEER Initiative: Precision Insights On N-of-1 Effectiveness Research. Tissue Ownership by the... NCT ID: NCT03896958 State: Georgia Investigator/Sponsoring Organization: SpeciCare |
Georgia | SpeciCare |
| Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects With High Risk Non-muscle Invas... NCT ID: NCT02625961 State: Multi-State Trial Investigator/Sponsoring Organization: Merck Sharp & Dohme Corp. |
Multi-State Trial | Merck Sharp & Dohme Corp. |
| Afatinib Dimaleate in Treating Patients With Advanced Refractory Urothelial Cancer NCT ID: NCT02122172 State: Multi-State Trial Investigator/Sponsoring Organization: University of Chicago |
Multi-State Trial | University of Chicago |
| Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX -2011 and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhib... NCT ID: NCT03989362 State: Multi-State Trial Investigator/Sponsoring Organization: Jounce Therapeutics, Inc. |
Multi-State Trial | Jounce Therapeutics, Inc. |
| Study of INBRX 106 in Subjects With Locally Advanced or Metastatic Solid Tumors NCT ID: NCT04198766 State: Multi-State Trial Investigator/Sponsoring Organization: Inhibrx, Inc. |
Multi-State Trial | Inhibrx, Inc. |
| Study to Collect Long-term Data on Participants From Multiple Avelumab (MSB0010718C) Clinical Studie... NCT ID: NCT03815643 State: Multi-State Trial Investigator/Sponsoring Organization: EMD Serono Research & Development Institute, Inc. |
Multi-State Trial | EMD Serono Research & Development Institute, Inc. |
| Study of the Safety, Tolerability and Feasibility of Gene-edited Autologous NeoTCR-T Cells (NeoTCR-P... NCT ID: NCT03970382 State: Multi-State Trial Investigator/Sponsoring Organization: PACT Pharma, Inc. |
Multi-State Trial | PACT Pharma, Inc. |
| Phase 1/1b Study of the Safety of TTX-030 as a Single Agent and in Combination With Pembrolizumab or... NCT ID: NCT03884556 State: Multi-State Trial Investigator/Sponsoring Organization: Trishula Therapeutics, Inc. |
Multi-State Trial | Trishula Therapeutics, Inc. |
| Assessment of Reliability of Cystoscopic Evaluation Predicting pT0 Urothelial Carcinoma of the Bladd... NCT ID: NCT02968732 State: Pennsylvania Investigator/Sponsoring Organization: Fox Chase Cancer Center |
Pennsylvania | Fox Chase Cancer Center |
| A Phase II Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 Inhibitor in C... NCT ID: NCT03737123 State: Multi-State Trial Investigator/Sponsoring Organization: Nabil Adra |
Multi-State Trial | Nabil Adra |
| LCI-GU-URO-CRI-001: Study of Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial... NCT ID: NCT02612194 State: North Carolina Investigator/Sponsoring Organization: Earle Burgess |
North Carolina | Earle Burgess |
| Study of In Situ Vaccination With Tremelimumab and IV Durvalumab (MEDI4736) Plus the Toll-like Recep... NCT ID: NCT02643303 State: Multi-State Trial Investigator/Sponsoring Organization: Ludwig Institute for Cancer Research |
Multi-State Trial | Ludwig Institute for Cancer Research |
| Study of A166 in Locally Advanced/Metastatic Solid Tumors Expressing Human Epidermal Growth Factor R... NCT ID: NCT03602079 State: Multi-State Trial Investigator/Sponsoring Organization: Klus Pharma Inc. |
Multi-State Trial | Klus Pharma Inc. |
| Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients With Muscle-Invasive Bladder Cance... NCT ID: NCT03609216 State: Multi-State Trial Investigator/Sponsoring Organization: Alliance for Clinical Trials in Oncology |
Multi-State Trial | Alliance for Clinical Trials in Oncology |
| Intraoperative Intravesical Instillation of Mitomycin C During Nephroureterectomy for Urothelial Car... NCT ID: NCT03658304 State: Florida Investigator/Sponsoring Organization: University of Florida |
Florida | University of Florida |
| First-Line Durvalumab in Combination With Standard of Care Chemotherapy and Durvalumab in Combinatio... NCT ID: NCT03682068 State: Multi-State Trial Investigator/Sponsoring Organization: AstraZeneca |
Multi-State Trial | AstraZeneca |
| Study of Olaparib (AZD2281) in Patients With Metastatic/Advanced Urothelial Carcinoma With DNA-Repai... NCT ID: NCT03375307 State: Multi-State Trial Investigator/Sponsoring Organization: National Cancer Institute (NCI) |
Multi-State Trial | National Cancer Institute (NCI) |
| Combination Therapy With Pemetrexed and Avelumab in Previously Treated Patients With MTAP-Deficient ... NCT ID: NCT03744793 State: Texas Investigator/Sponsoring Organization: M.D. Anderson Cancer Center |
Texas | M.D. Anderson Cancer Center |
| Solid Tumor Cancer Surgery With or Without Intraoperative Imaging: A Registry Optional Sub-Study I: ... NCT ID: NCT02852252 State: Pennsylvania Investigator/Sponsoring Organization: University of Pennsylvania |
Pennsylvania | University of Pennsylvania |
| Study of Rucaparib as Treatment for Solid Tumors Associated With Deleterious Mutations in Homologous... NCT ID: NCT04171700 State: Multi-State Trial Investigator/Sponsoring Organization: Clovis Oncology, Inc. |
Multi-State Trial | Clovis Oncology, Inc. |
| Study to Evaluate the Safety of Neoadjuvant Nivolumab Alone or in Combination With Ipilimumab for Ci... NCT ID: NCT03520491 State: Multi-State Trial Investigator/Sponsoring Organization: Memorial Sloan Kettering Cancer Center |
Multi-State Trial | Memorial Sloan Kettering Cancer Center |
| Nivolumab in Combination With Intravesical BCG Versus Standard of Care BCG Alone in Participants Wit... NCT ID: NCT04149574 State: Multi-State Trial Investigator/Sponsoring Organization: Bristol-Myers Squibb |
Multi-State Trial | Bristol-Myers Squibb |
| Radiation Therapy and Anti-PD-L1 Checkpoint Inhibitor (Durvalumab) With or Without Anti-CTLA-4 Inhib... NCT ID: NCT03601455 State: California Investigator/Sponsoring Organization: Jonsson Comprehensive Cancer Center |
California | Jonsson Comprehensive Cancer Center |
| Intra-corporal vs Extra-corporal Urinary Diversion After Robot Assisted Radical Cystectomy NCT ID: NCT03469362 State: Florida Investigator/Sponsoring Organization: University of Miami |
Florida | University of Miami |
| Defining the Genomic and Histologic Landscape of Primary and Metastatic Tumors With Divergent Kineti... NCT ID: NCT03291028 State: Pennsylvania Investigator/Sponsoring Organization: Fox Chase Cancer Center |
Pennsylvania | Fox Chase Cancer Center |
| Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) With Pembrolizumab, in Subjects Who Have... NCT ID: NCT03935347 State: New York Investigator/Sponsoring Organization: Roswell Park Cancer Institute |
New York | Roswell Park Cancer Institute |
| Study to Evaluate the Safety, Tolerability, Maximum Tolerated or Administered Dose, Pharmacokinetics... NCT ID: NCT03666273 State: Multi-State Trial Investigator/Sponsoring Organization: Bayer |
Multi-State Trial | Bayer |
| Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) NCT ID: NCT03866382 State: Multi-State Trial Investigator/Sponsoring Organization: National Cancer Institute (NCI) |
Multi-State Trial | National Cancer Institute (NCI) |
| A Phase 1b/2, Open-Label, Multicenter Dose-Escalation and Dose-Expansion Study of the Combination of... NCT ID: NCT03989115 State: Multi-State Trial Investigator/Sponsoring Organization: Revolution Medicines, Inc. |
Multi-State Trial | Revolution Medicines, Inc. |
| Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD... NCT ID: NCT03547973 State: Multi-State Trial Investigator/Sponsoring Organization: Immunomedics, Inc. |
Multi-State Trial | Immunomedics, Inc. |
| Intensive Preoperative Ostomy Education for the Radical Cystectomy Patient NCT ID: NCT03462667 State: Kansas Investigator/Sponsoring Organization: University of Kansas Medical Center |
Kansas | University of Kansas Medical Center |
| Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203) NCT ID: NCT03679767 State: Multi-State Trial Investigator/Sponsoring Organization: Incyte Corporation |
Multi-State Trial | Incyte Corporation |
| Tazemetostat and MK-3475 (Pembrolizumab) in Advanced Urothelial Carcinoma NCT ID: NCT03854474 State: Multi-State Trial Investigator/Sponsoring Organization: National Cancer Institute (NCI) |
Multi-State Trial | National Cancer Institute (NCI) |
| Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors NCT ID: NCT03767348 State: Multi-State Trial Investigator/Sponsoring Organization: Replimune Inc. |
Multi-State Trial | Replimune Inc. |
| Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Lenvatinib (E7080/MK-7902) Versus... NCT ID: NCT03898180 State: Multi-State Trial Investigator/Sponsoring Organization: Merck Sharp & Dohme Corp. |
Multi-State Trial | Merck Sharp & Dohme Corp. |
| Familial and Atypical Urothelial Cancer Registry NCT ID: NCT00902590 State: Multi-State Trial Investigator/Sponsoring Organization: Memorial Sloan Kettering Cancer Center |
Multi-State Trial | Memorial Sloan Kettering Cancer Center |
| Tremelimumab in Patients With Metastatic Urothelial Cancer Previously Treated With PD-1/PD-L1 Blocka... NCT ID: NCT03557918 State: Multi-State Trial Investigator/Sponsoring Organization: Matthew Galsky |
Multi-State Trial | Matthew Galsky |
| Prevalence of PD-L1 Expression in the First-Line Setting of Locally Advanced/Unresectable or Metasta... NCT ID: NCT03788746 State: Multi-State Trial Investigator/Sponsoring Organization: AstraZeneca |
Multi-State Trial | AstraZeneca |
| Molecular Correlates of Sensitivity and Resistance to Therapy in Genitourinary Malignancy NCT ID: NCT01050504 State: Washington Investigator/Sponsoring Organization: University of Washington |
Washington | University of Washington |
| Phase II Trial of AZD6738 Alone and in Combination With Olaparib in Patients With Selected Solid Tum... NCT ID: NCT03682289 State: California Investigator/Sponsoring Organization: Rahul Aggarwal |
California | Rahul Aggarwal |
| Study of MGA271 in Combination With Pembrolizumab and in Combination With MGA012 in Patients With Ur... NCT ID: NCT02475213 State: Multi-State Trial Investigator/Sponsoring Organization: MacroGenics |
Multi-State Trial | MacroGenics |
| Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermedi... NCT ID: NCT03914794 State: Maryland Investigator/Sponsoring Organization: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Maryland | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
| Trial Evaluating the Length of Treatment With PD-1/PD-L1 Inhibitors in Patients With Advanced Solid ... NCT ID: NCT04157985 State: Pennsylvania Investigator/Sponsoring Organization: Antoinette J Wozniak |
Pennsylvania | Antoinette J Wozniak |
| Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects Wit... NCT ID: NCT03170960 State: Multi-State Trial Investigator/Sponsoring Organization: Exelixis |
Multi-State Trial | Exelixis |
| Study of Adjuvant 3D-Conformal Radiotherapy in High Risk Bladder Cancer NCT ID: NCT01954173 State: Georgia Investigator/Sponsoring Organization: Emory University |
Georgia | Emory University |
| sEphB4-HSA in Combination With Anti PD1 Antibody Pembrolizumab (MK-7435) for Metastatic Urothelial C... NCT ID: NCT02717156 State: Multi-State Trial Investigator/Sponsoring Organization: University of Southern California |
Multi-State Trial | University of Southern California |
| Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN BLADDER) NCT ID: NCT02710734 State: Multi-State Trial Investigator/Sponsoring Organization: Fox Chase Cancer Center |
Multi-State Trial | Fox Chase Cancer Center |
| Study to Evaluate the Efficacy and Safety of Nivolumab Administered in Combination With IPI-549 Comp... NCT ID: NCT03980041 State: Multi-State Trial Investigator/Sponsoring Organization: Infinity Pharmaceuticals, Inc. |
Multi-State Trial | Infinity Pharmaceuticals, Inc. |
| Atezolizumab in Combination With Gemcitabine and Cisplatin As First-Line Treatment in Metastatic Uro... NCT ID: NCT03093922 State: Multi-State Trial Investigator/Sponsoring Organization: Memorial Sloan Kettering Cancer Center |
Multi-State Trial | Memorial Sloan Kettering Cancer Center |
| Study to Evaluate the Activity of Commercially Available Molecularly Matched Targeted Therapies in S... NCT ID: NCT02795156 State: Multi-State Trial Investigator/Sponsoring Organization: SCRI Development Innovations, LLC |
Multi-State Trial | SCRI Development Innovations, LLC |
| Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects With Advance... NCT ID: NCT03390504 State: Multi-State Trial Investigator/Sponsoring Organization: Janssen Research & Development, LLC |
Multi-State Trial | Janssen Research & Development, LLC |
| Bacillus Calmette-Guérin (BCG) and Intravesical Gemcitabine for Patients With BCG-Relapsing High-Gra... NCT ID: NCT04179162 State: Multi-State Trial Investigator/Sponsoring Organization: Memorial Sloan Kettering Cancer Center |
Multi-State Trial | Memorial Sloan Kettering Cancer Center |
| An Open-label, Phase 1 Study of KHK2455 in Combination With Avelumab in Adult Subjects With Locally ... NCT ID: NCT03915405 State: Multi-State Trial Investigator/Sponsoring Organization: Kyowa Kirin Pharmaceutical Development, Inc. |
Multi-State Trial | Kyowa Kirin Pharmaceutical Development, Inc. |
| My Pathway: Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib,... NCT ID: NCT02091141 State: Multi-State Trial Investigator/Sponsoring Organization: Genentech, Inc. |
Multi-State Trial | Genentech, Inc. |
| Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes NCT ID: NCT03757949 State: Multi-State Trial Investigator/Sponsoring Organization: Southwest Oncology Group |
Multi-State Trial | Southwest Oncology Group |
| Study of Low-Dose Paclitaxel With Pembrolizumab in Platinum-Refractory Urothelial Carcinoma NCT ID: NCT02581982 State: North Carolina Investigator/Sponsoring Organization: Wake Forest University Health Sciences |
North Carolina | Wake Forest University Health Sciences |
| Study of Avelumab in Combination With Bladder-Directed Radiation in Cisplatin-Ineligible Patients Wi... NCT ID: NCT03747419 State: Multi-State Trial Investigator/Sponsoring Organization: Dana-Farber Cancer Institute |
Multi-State Trial | Dana-Farber Cancer Institute |
| Study of BC-819 in Patients With Non-Muscle Invasive Bladder Cancer Whose Disease is Unresponsive to... NCT ID: NCT03719300 State: Multi-State Trial Investigator/Sponsoring Organization: Anchiano Therapeutics Israel Ltd. |
Multi-State Trial | Anchiano Therapeutics Israel Ltd. |
| Study of the Treatment of Metastatic Cancer That Expresses MAGE-A3 Using Lymphodepleting Conditionin... NCT ID: NCT02111850 State: Maryland Investigator/Sponsoring Organization: National Cancer Institute (NCI) |
Maryland | National Cancer Institute (NCI) |
| Neoadjuvant Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer W... NCT ID: NCT03558087 State: Multi-State Trial Investigator/Sponsoring Organization: Matthew Galsky |
Multi-State Trial | Matthew Galsky |
| Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combi... NCT ID: NCT03678883 State: Multi-State Trial Investigator/Sponsoring Organization: Actuate Therapeutics Inc. |
Multi-State Trial | Actuate Therapeutics Inc. |
| Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36γ... NCT ID: NCT03739931 State: Multi-State Trial Investigator/Sponsoring Organization: ModernaTX, Inc. |
Multi-State Trial | ModernaTX, Inc. |
| Study of Enfortumab Vedotin (ASG-22CE) for Treatment of Patients With Locally Advanced or Metastatic... NCT ID: NCT03219333 State: Multi-State Trial Investigator/Sponsoring Organization: Astellas Pharma Global Development, Inc. |
Multi-State Trial | Astellas Pharma Global Development, Inc. |
| Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Perfo... NCT ID: NCT01224665 State: Multi-State Trial Investigator/Sponsoring Organization: Southwest Oncology Group |
Multi-State Trial | Southwest Oncology Group |
| Study for the Production of a Patient-Specific Neoantigen Cancer Vaccine and Screening Study for a S... NCT ID: NCT03794128 State: Multi-State Trial Investigator/Sponsoring Organization: Gritstone Oncology, Inc. |
Multi-State Trial | Gritstone Oncology, Inc. |
| Study of Regorafenib for Advanced Urothelial Cancer Following Prior Chemotherapy NCT ID: NCT02459119 State: Multi-State Trial Investigator/Sponsoring Organization: University of Alabama at Birmingham |
Multi-State Trial | University of Alabama at Birmingham |
| Study of INCB054828 in Subjects With Advanced Malignancies (FIGHT-101) NCT ID: NCT02393248 State: Multi-State Trial Investigator/Sponsoring Organization: Incyte Corporation |
Multi-State Trial | Incyte Corporation |
| Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent... NCT ID: NCT03821935 State: Multi-State Trial Investigator/Sponsoring Organization: AbbVie |
Multi-State Trial | AbbVie |
| Study of Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer (N... NCT ID: NCT03171025 State: Utah Investigator/Sponsoring Organization: University of Utah |
Utah | University of Utah |
| Genistein in Reducing the Toxicity and Improving the Efficacy of Intravesical Therapy NCT ID: NCT01489813 State: Multi-State Trial Investigator/Sponsoring Organization: Emory University |
Multi-State Trial | Emory University |
| A Patient-Centered Approach to Integration of Life Expectancy Into Treatment Decision Making for Pat... NCT ID: NCT03522155 State: California Investigator/Sponsoring Organization: Cedars-Sinai Medical Center |
California | Cedars-Sinai Medical Center |
| CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer NCT ID: NCT03933826 State: Multi-State Trial Investigator/Sponsoring Organization: University of Washington |
Multi-State Trial | University of Washington |
| Imaging of Bladder Cancer Using Clinical 3 Tesla MRI and EX-VIVO Ultra-High-Field MRI. NCT ID: NCT00938145 State: Ohio Investigator/Sponsoring Organization: Ohio State University Comprehensive Cancer Center |
Ohio | Ohio State University Comprehensive Cancer Center |
| Study of Durvalumab With Neoadjuvant Chemotherapy in Variant Histology Bladder Cancer NCT ID: NCT03912818 State: California Investigator/Sponsoring Organization: Stanford University |
California | Stanford University |
| GU-114: Overcoming Checkpoint Inhibitor Resistance With Epigenetic Therapy in Urothelial Cancer NCT ID: NCT03179943 State: Multi-State Trial Investigator/Sponsoring Organization: Fox Chase Cancer Center |
Multi-State Trial | Fox Chase Cancer Center |
| Phase II Trial of Concurrent Nivolumab in Urothelial Bladder Cancer With Radiation Therapy in Locali... NCT ID: NCT03421652 State: Multi-State Trial Investigator/Sponsoring Organization: Barbara Ann Karmanos Cancer Institute |
Multi-State Trial | Barbara Ann Karmanos Cancer Institute |
| Study to Evaluate the Activity and Tolerability of the Novel mTOR Inhibitor, MLN0128 (TAK-228), in P... NCT ID: NCT03047213 State: Multi-State Trial Investigator/Sponsoring Organization: National Cancer Institute (NCI) |
Multi-State Trial | National Cancer Institute (NCI) |
| DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors NCT ID: NCT02834013 State: Multi-State Trial Investigator/Sponsoring Organization: National Cancer Institute (NCI) |
Multi-State Trial | National Cancer Institute (NCI) |
| Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, Alone and in Combination With an Anti-PD-1 in P... NCT ID: NCT03250832 State: Multi-State Trial Investigator/Sponsoring Organization: Tesaro, Inc. |
Multi-State Trial | Tesaro, Inc. |
| udy to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK332659... NCT ID: NCT02783300 State: Multi-State Trial Investigator/Sponsoring Organization: GlaxoSmithKline |
Multi-State Trial | GlaxoSmithKline |
| Window of Opportunity Platform Study to Define Immunogenomic Changes With Pembrolizumab Alone and in... NCT ID: NCT03978624 State: North Carolina Investigator/Sponsoring Organization: UNC Lineberger Comprehensive Cancer Center |
North Carolina | UNC Lineberger Comprehensive Cancer Center |
| Prevention of Parastomal Hernia Following Radical Cystectomy and Ileal Conduit Using Biologic Mesh: ... NCT ID: NCT02439060 State: California Investigator/Sponsoring Organization: University of Southern California |
California | University of Southern California |
| Study of Check Point Inhibitor, Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refractory ... NCT ID: NCT02901548 State: Multi-State Trial Investigator/Sponsoring Organization: H. Lee Moffitt Cancer Center and Research Institute |
Multi-State Trial | H. Lee Moffitt Cancer Center and Research Institute |
| PF-06801591, an Anti-PD-1 Antibody, in Combination With Bacillus Calmette-Guerin (BCG Induction With... NCT ID: NCT04165317 State: Multi-State Trial Investigator/Sponsoring Organization: Pfizer |
Multi-State Trial | Pfizer |
| STUDY TO EVALUATE SAFETY, CLINICAL ACTIVITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB (MSB0... NCT ID: NCT02554812 State: Multi-State Trial Investigator/Sponsoring Organization: Pfizer |
Multi-State Trial | Pfizer |
| Antitumor Activity of BDTX-189, an Inhibitor of Allosteric ErbB Mutations, in Patients w/ Advanced S... NCT ID: NCT04209465 State: Multi-State Trial Investigator/Sponsoring Organization: Black Diamond Therapeutics, Inc. |
Multi-State Trial | Black Diamond Therapeutics, Inc. |
| Pilot Testing for Post-Cystectomy mHealth Tool to Improve Perioperative Care NCT ID: NCT03862105 State: North Carolina Investigator/Sponsoring Organization: UNC Lineberger Comprehensive Cancer Center |
North Carolina | UNC Lineberger Comprehensive Cancer Center |
| Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial C... NCT ID: NCT03534804 State: Multi-State Trial Investigator/Sponsoring Organization: University of Utah |
Multi-State Trial | University of Utah |
| Trial of Preventive Mesh Placement at the Time of Radical Cystectomy to Reduce the Chances of Develo... NCT ID: NCT02908061 State: Multi-State Trial Investigator/Sponsoring Organization: Memorial Sloan Kettering Cancer Center |
Multi-State Trial | Memorial Sloan Kettering Cancer Center |
| Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy Versus Perioperat... NCT ID: NCT03924856 State: Multi-State Trial Investigator/Sponsoring Organization: Merck Sharp & Dohme Corp. |
Multi-State Trial | Merck Sharp & Dohme Corp. |
| Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With BC... NCT ID: NCT03022825 State: Multi-State Trial Investigator/Sponsoring Organization: ImmunityBio, Inc. |
Multi-State Trial | ImmunityBio, Inc. |
| Trial of Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cispl... NCT ID: NCT03451331 State: Multi-State Trial Investigator/Sponsoring Organization: Matthew Galsky |
Multi-State Trial | Matthew Galsky |
| Study of NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD... NCT ID: NCT03589339 State: Multi-State Trial Investigator/Sponsoring Organization: Nanobiotix |
Multi-State Trial | Nanobiotix |
| Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillu... NCT ID: NCT04172675 State: Multi-State Trial Investigator/Sponsoring Organization: Janssen Research & Development, LLC |
Multi-State Trial | Janssen Research & Development, LLC |
| Molecular Analysis for Therapy Choice (MATCH) NCT ID: NCT02465060 State: Multi-State Trial Investigator/Sponsoring Organization: National Cancer Institute (NCI) |
Multi-State Trial | National Cancer Institute (NCI) |
| Atezolizumab and Bevacizumab in Cisplatin-ineligible Patients With Advanced/Unresectable Urothelial ... NCT ID: NCT03272217 State: Multi-State Trial Investigator/Sponsoring Organization: Arjun Balar, MD |
Multi-State Trial | Arjun Balar, MD |
| Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Metastatic or... NCT ID: NCT02872714 State: Multi-State Trial Investigator/Sponsoring Organization: Incyte Corporation |
Multi-State Trial | Incyte Corporation |
| Trial of MK3475 in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy as... NCT ID: NCT02621151 State: Multi-State Trial Investigator/Sponsoring Organization: NYU Langone Health |
Multi-State Trial | NYU Langone Health |
| Trial With Expansion Cohorts to Evaluate Safety of GEN1029 in Patients With Malignant Solid Tumors NCT ID: NCT03576131 State: Multi-State Trial Investigator/Sponsoring Organization: Genmab |
Multi-State Trial | Genmab |
| Trial of Alvimopan (Entereg) Versus Placebo in Patients Undergoing Radical Cystectomy and Urinary Di... NCT ID: NCT03216525 State: Massachusetts Investigator/Sponsoring Organization: Brigham and Women's Hospital |
Massachusetts | Brigham and Women's Hospital |
| Ex-Vivo Trial of En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using Mo... NCT ID: NCT04235764 State: Maryland Investigator/Sponsoring Organization: National Cancer Institute (NCI) |
Maryland | National Cancer Institute (NCI) |
| Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer NCT ID: NCT03674567 State: Multi-State Trial Investigator/Sponsoring Organization: RAPT Therapeutics, Inc. |
Multi-State Trial | RAPT Therapeutics, Inc. |
| Evaluation for NCI Surgery Branch Clinical Research Protocols NCT ID: NCT00001823 State: Maryland Investigator/Sponsoring Organization: National Cancer Institute (NCI) |
Maryland | National Cancer Institute (NCI) |
| Study of Motility Contrast Tomography for Predicting Therapeutic Response NCT ID: NCT03739177 State: Indiana Investigator/Sponsoring Organization: Animated Dynamics, Inc. |
Indiana | Animated Dynamics, Inc. |
| Cisplatin/Gemcitabine With or Without M6620 (VX-970) in Metastatic Urothelial Carcinoma NCT ID: NCT02567409 State: Multi-State Trial Investigator/Sponsoring Organization: National Cancer Institute (NCI) |
Multi-State Trial | National Cancer Institute (NCI) |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry NCT ID: NCT03452774 State: New York Investigator/Sponsoring Organization: Massive Bio, Inc. |
New York | Massive Bio, Inc. |
| Study of Gemcitabine and Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Prior to Radical Cystec... NCT ID: NCT02690558 State: Multi-State Trial Investigator/Sponsoring Organization: UNC Lineberger Comprehensive Cancer Center |
Multi-State Trial | UNC Lineberger Comprehensive Cancer Center |
| Cabozantinib in Combination With Pemetrexed in Advanced Non-squamous Non-small Cell Lung Cancer (NSC... NCT ID: NCT04173338 State: Georgia Investigator/Sponsoring Organization: Augusta University |
Georgia | Augusta University |
| Genetic Susceptibility to Bladder Cancer: A Molecular Epidemiology Approach NCT ID: NCT00848289 State: Multi-State Trial Investigator/Sponsoring Organization: M.D. Anderson Cancer Center |
Multi-State Trial | M.D. Anderson Cancer Center |
| Trial of Alvimopan (Entereg) Versus Placebo in Patients Undergoing Radical Cystectomy and Urinary Di... NCT ID: NCT03216525 State: Massachusetts Investigator/Sponsoring Organization: Brigham and Women's Hospital |
Massachusetts | Brigham and Women's Hospital |
| Early Intervention for Impairments Identified During Comprehensive Geriatric Assessment in Patients ... NCT ID: NCT04273724 State: North Carolina Investigator/Sponsoring Organization: UNC Lineberger Comprehensive Cancer Center |
North Carolina | UNC Lineberger Comprehensive Cancer Center |
| Measuring Surgical Recovery After Radical Cystectomy NCT ID: NCT03193970 State: Multi-State Trial Investigator/Sponsoring Organization: M.D. Anderson Cancer Center |
Multi-State Trial | M.D. Anderson Cancer Center |
| Study of Nivolumab Combined With Ipilimumab, or With Standard of Care Chemotherapy, Versus Standard ... NCT ID: NCT03036098 State: Multi-State Trial Investigator/Sponsoring Organization: Bristol-Myers Squibb |
Multi-State Trial | Bristol-Myers Squibb |
| Study of First-Line MEDI4736 (Durvalumab) Monotherapy and MEDI4736 (Durvalumab) in Combination With ... NCT ID: NCT02516241 State: Multi-State Trial Investigator/Sponsoring Organization: AstraZeneca |
Multi-State Trial | AstraZeneca |
| Continuous Bladder Irrigation Following Transurethral Resection of Bladder Tumors NCT ID: NCT03839472 State: Ohio Investigator/Sponsoring Organization: Case Comprehensive Cancer Center |
Ohio | Case Comprehensive Cancer Center |
| Study of KYN-175, an Oral Aryl Hydrocarbon Receptor (AHR) Inhibitor in Patients With Locally Advance... NCT ID: NCT04200963 State: Multi-State Trial Investigator/Sponsoring Organization: Ikena Oncology |
Multi-State Trial | Ikena Oncology |
| Trial of Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With... NCT ID: NCT04197986 State: Multi-State Trial Investigator/Sponsoring Organization: QED Therapeutics, Inc. |
Multi-State Trial | QED Therapeutics, Inc. |
| Stereotactic Ablative Radiation (SAbR) for Urothelial Cancer Patients With Progression While on Anti... NCT ID: NCT04131634 State: Texas Investigator/Sponsoring Organization: University of Texas Southwestern Medical Center |
Texas | University of Texas Southwestern Medical Center |
| Study of Avelumab in Combination With AXL Inhibitor AVB-S6-500 in Patients With Advanced Urothelial ... NCT ID: NCT04004442 State: Multi-State Trial Investigator/Sponsoring Organization: University of Oklahoma |
Multi-State Trial | University of Oklahoma |
| St. Judes-Stanford Comprehensive Support Initiative NCT ID: NCT03154190 State: California Investigator/Sponsoring Organization: Stanford University |
California | Stanford University |
| Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without Chemotherapy, Versus C... NCT ID: NCT04223856 State: Multi-State Trial Investigator/Sponsoring Organization: Astellas Pharma Global Development, Inc. |
Multi-State Trial | Astellas Pharma Global Development, Inc. |
| Using Patient Centered Data and Behavioral Economics to Improve Mobility and Reduce Readmissions Aft... NCT ID: NCT04314778 State: Multi-State Trial Investigator/Sponsoring Organization: University of Pennsylvania |
Multi-State Trial | University of Pennsylvania |
| Study of Pembrolizumab (MK-3475) as First-Line Therapy for High Risk T1 Non-Muscle-Invasive Bladder ... NCT ID: NCT03504163 State: Multi-State Trial Investigator/Sponsoring Organization: Memorial Sloan Kettering Cancer Center |
Multi-State Trial | Memorial Sloan Kettering Cancer Center |
| Study of SKB264 in Patients With Locally Advanced Unresectable /Metastatic Solid Tumors Who Are Refr... NCT ID: NCT04152499 State: Multi-State Trial Investigator/Sponsoring Organization: Klus Pharma Inc. |
Multi-State Trial | Klus Pharma Inc. |
| Hypofractionated Radiotherapy in Patients With Limited Progression on Immune Checkpoint Blockade NCT ID: NCT03693014 State: Multi-State Trial Investigator/Sponsoring Organization: Memorial Sloan Kettering Cancer Center |
Multi-State Trial | Memorial Sloan Kettering Cancer Center |
| Image-Guided Gynecologic Brachytherapy In The MR Simulator Suite NCT ID: NCT02993900 State: Maryland Investigator/Sponsoring Organization: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Maryland | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
| Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tu... NCT ID: NCT04344795 State: Multi-State Trial Investigator/Sponsoring Organization: Tempest Therapeutics |
Multi-State Trial | Tempest Therapeutics |
| Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients NCT ID: NCT00579514 State: New York Investigator/Sponsoring Organization: Memorial Sloan Kettering Cancer Center |
New York | Memorial Sloan Kettering Cancer Center |
| INtravesical STING Agonist E7766 in NMIBC Including Subjects Unresponsive to BCG Therapy, INPUT-102 NCT ID: NCT04109092 State: Multi-State Trial Investigator/Sponsoring Organization: Eisai Inc. |
Multi-State Trial | Eisai Inc. |
| miR Sentinel™ BCa Test in Men and Women Presenting for Initial Diagnosis of Bladder Cancer and the m... NCT ID: NCT04155359 State: New York Investigator/Sponsoring Organization: miR Scientific LLC |
New York | miR Scientific LLC |
| Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT)... NCT ID: NCT04241185 State: Multi-State Trial Investigator/Sponsoring Organization: Merck Sharp & Dohme Corp. |
Multi-State Trial | Merck Sharp & Dohme Corp. |
| ABLE: Abraxane With Anti-PD1/PDL1 in Patients With Advanced Urothelial Cancer NCT ID: NCT03240016 State: Michigan Investigator/Sponsoring Organization: University of Michigan Rogel Cancer Center |
Michigan | University of Michigan Rogel Cancer Center |
| SGN-B6A in Advanced Solid Tumors NCT ID: NCT04389632 State: Multi-State Trial Investigator/Sponsoring Organization: Seagen Inc. |
Multi-State Trial | Seagen Inc. |
| Study of CAbozantinib in Combination With AtezolizumaB as NeoAdjuvant Treatment for Muscle-Invasive... NCT ID: NCT04289779 State: Multi-State Trial Investigator/Sponsoring Organization: Deepak Kilari |
Multi-State Trial | Deepak Kilari |
| Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention NCT ID: NCT04375813 State: Multi-State Trial Investigator/Sponsoring Organization: Rapamycin Holdings, Inc. dba Emtora Biosciences |
Multi-State Trial | Rapamycin Holdings, Inc. dba Emtora Biosciences |
| Study of Bintrafusp Alfa (M7824) and NHS-IL12 (M9241) Alone and in Combination With Stereotactic Bod... NCT ID: NCT04235777 State: Maryland Investigator/Sponsoring Organization: National Cancer Institute (NCI) |
Maryland | National Cancer Institute (NCI) |
| APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies NCT ID: NCT04383938 State: Multi-State Trial Investigator/Sponsoring Organization: Aprea Therapeutics |
Multi-State Trial | Aprea Therapeutics |
| Study of AN0025 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors NCT ID: NCT04432857 State: Multi-State Trial Investigator/Sponsoring Organization: Adlai Nortye Biopharma Co., Ltd. |
Multi-State Trial | Adlai Nortye Biopharma Co., Ltd. |
| Pharmacokinetic Multi-tumor Study of Subcutaneous Formulation of Ipilimumab Monotherapy and in Combi... NCT ID: NCT04311710 State: Multi-State Trial Investigator/Sponsoring Organization: Bristol-Myers Squibb |
Multi-State Trial | Bristol-Myers Squibb |
| Genetic Modifiers of 22q11.2 Deletion Syndrome NCT ID: NCT00556530 State: Multi-State Trial Investigator/Sponsoring Organization: Albert Einstein College of Medicine |
Multi-State Trial | Albert Einstein College of Medicine |
| Trial of CRLX101, a Nanoparticle Camptothecin With Olaparib in Patients With Relapsed/Refractory Sma... NCT ID: NCT02769962 State: Maryland Investigator/Sponsoring Organization: National Cancer Institute (NCI) |
Maryland | National Cancer Institute (NCI) |
| Study to Evaluate Long Term Safety and Efficacy in Patients Who Are Receiving or Who Previously Rece... NCT ID: NCT04078152 State: Multi-State Trial Investigator/Sponsoring Organization: AstraZeneca |
Multi-State Trial | AstraZeneca |
| Pembrolizumab and aMVAC Chemotherapy as Neoadjuvant Therapy in Non-Urothelial Histology Muscle-Invas... NCT ID: NCT04383743 State: Washington Investigator/Sponsoring Organization: University of Washington |
Washington | University of Washington |
| Study To Assess Whether A Preoperative Tumor Biopsy Can Improve Upon The Endoscopic Impression Deter... NCT ID: NCT02992990 State: Texas Investigator/Sponsoring Organization: Baylor College of Medicine |
Texas | Baylor College of Medicine |
| Study of EDP1503 Alone and in Combination With Pembrolizumab in Patients With Advanced Metastatic Co... NCT ID: NCT03775850 State: Multi-State Trial Investigator/Sponsoring Organization: Evelo Biosciences, Inc. |
Multi-State Trial | Evelo Biosciences, Inc. |
| Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies NCT ID: NCT04440943 State: Georgia Investigator/Sponsoring Organization: Celldex Therapeutics |
Georgia | Celldex Therapeutics |
| Use of Intravesical Gemcitabine and Docetaxel (GEMDOCE) in the Treatment of BCG naïve Non-muscle Inv... NCT ID: NCT04386746 State: Maryland Investigator/Sponsoring Organization: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Maryland | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
| Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy NCT ID: NCT04442724 State: Multi-State Trial Investigator/Sponsoring Organization: Cedars-Sinai Medical Center |
Multi-State Trial | Cedars-Sinai Medical Center |
| Study to Evaluate the Safety of TTX-080, an HLA-G Antagonist, in Subjects With Advanced Solid Tumor... NCT ID: NCT04485013 State: Multi-State Trial Investigator/Sponsoring Organization: Tizona Therapeutics, Inc |
Multi-State Trial | Tizona Therapeutics, Inc |
| Study of RMC-4630 Monotherapy in Adult Participants With Relapsed/Refractory Solid Tumors NCT ID: NCT03634982 State: Multi-State Trial Investigator/Sponsoring Organization: Revolution Medicines, Inc. |
Multi-State Trial | Revolution Medicines, Inc. |
| Neoadjuvant Infigratinib, an Inhibitor of FGFR, in Upper Tract Urothelial Carcinoma NCT ID: NCT04228042 State: Texas Investigator/Sponsoring Organization: M.D. Anderson Cancer Center |
Texas | M.D. Anderson Cancer Center |
| Neoadjuvant Infigratinib, an Inhibitor of FGFR, in Upper Tract Urothelial Carcinoma NCT ID: NCT04228042 State: Texas Investigator/Sponsoring Organization: M.D. Anderson Cancer Center |
Texas | M.D. Anderson Cancer Center |
| GEN1044 in Subjects With Malignant Solid Tumors NCT ID: NCT04424641 State: Multi-State Trial Investigator/Sponsoring Organization: Genmab |
Multi-State Trial | Genmab |
| Does Prophylactic Antibiotic Decrease the Rate of Urinary Tract Infection After Robot Assisted Radic... NCT ID: NCT04502095 State: New York Investigator/Sponsoring Organization: Roswell Park Cancer Institute |
New York | Roswell Park Cancer Institute |
| Anti-IL1RAP Monoclonal Antibody, in Combination With Pembrolizumab in Subjects With Solid Tumors Pro... NCT ID: NCT04452214 State: Multi-State Trial Investigator/Sponsoring Organization: Cantargia AB |
Multi-State Trial | Cantargia AB |
| CAN04, a Fully Humanized Anti-IL1RAP Monoclonal Antibody, in Combination With Pembrolizumab in Subj... NCT ID: NCT04452214 State: Multi-State Trial Investigator/Sponsoring Organization: Cantargia AB |
Multi-State Trial | Cantargia AB |
| Eribulin Mesylate in Combination With Atezolizumab Compared to Atezolizumab Alone in Subjects With L... NCT ID: NCT03237780 State: Multi-State Trial Investigator/Sponsoring Organization: National Cancer Institute (NCI) |
Multi-State Trial | National Cancer Institute (NCI) |
| Eribulin Mesylate in Combination With Atezolizumab Compared to Atezolizumab Alone in Subjects With L... NCT ID: NCT03237780 State: Multi-State Trial Investigator/Sponsoring Organization: National Cancer Institute (NCI) |
Multi-State Trial | National Cancer Institute (NCI) |
| Dietary Intervention to Improve Bladder Cancer Survivorship NCT ID: NCT04548193 State: New York Investigator/Sponsoring Organization: Roswell Park Cancer Institute |
New York | Roswell Park Cancer Institute |
| Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTI... NCT ID: NCT04482309 State: Multi-State Trial Investigator/Sponsoring Organization: AstraZeneca |
Multi-State Trial | AstraZeneca |
| Study of ACE1702 Cell Immunotherapy in Subjects With Advanced or Metastatic HER2-expressing Solid Tu... NCT ID: NCT04319757 State: Multi-State Trial Investigator/Sponsoring Organization: Acepodia Biotech Inc. |
Multi-State Trial | Acepodia Biotech Inc. |
| Bladder-SparIng Chemoradiation With MEDI4736 (Durvalumab) in Clinical Stage 3, Node PosItive Bladder... NCT ID: NCT04216290 State: Multi-State Trial Investigator/Sponsoring Organization: National Cancer Institute (NCI) |
Multi-State Trial | National Cancer Institute (NCI) |
| Investigating Marrow Infiltrating Lymphocytes as a Source of Adoptive Cellular Therapy in Renal Cell... NCT ID: NCT04341740 State: Oklahoma Investigator/Sponsoring Organization: University of Oklahoma |
Oklahoma | University of Oklahoma |
| DF6002 as a Monotherapy and in Combination With Pembrolizumab in Patients With Locally Advanced or M... NCT ID: NCT04423029 State: Rhode Island Investigator/Sponsoring Organization: Dragonfly Therapeutics |
Rhode Island | Dragonfly Therapeutics |
| DS3201 With Ipilimumab in Patients With Metastatic Aggressive Variant Prostate (AVPC), Urothelial (U... NCT ID: NCT04388852 State: Texas Investigator/Sponsoring Organization: M.D. Anderson Cancer Center |
Texas | M.D. Anderson Cancer Center |
| Activity of BT8009 in Patients With Nectin-4 Expressing Advanced Malignancies NCT ID: NCT04561362 State: Multi-State Trial Investigator/Sponsoring Organization: Bicycle Tx Limited |
Multi-State Trial | Bicycle Tx Limited |
| A Phase II Study of TAS-102 in Metastatic Platinum and Checkpoint Inhibitor-resistant Bladder Cancer NCT ID: NCT03762161 State: Multi-State Trial Investigator/Sponsoring Organization: Rahul Parikh |
Multi-State Trial | Rahul Parikh |
| Study of FT516 in Combination With Monoclonal Antibodies in Subjects With Advanced Solid Tumors NCT ID: NCT04551885 State: Multi-State Trial Investigator/Sponsoring Organization: Fate Therapeutics |
Multi-State Trial | Fate Therapeutics |
| Pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Subjects With Metastatic or Surgically Unresectab... NCT ID: NCT02365597 State: Multi-State Trial Investigator/Sponsoring Organization: Janssen Research & Development, LLC |
Multi-State Trial | Janssen Research & Development, LLC |
| Virtual Histology of the Bladder Wall for Bladder Cancer Staging; A Novel Intravesical Contrast-Enha... NCT ID: NCT04369560 State: Pennsylvania Investigator/Sponsoring Organization: Jodi Maranchie |
Pennsylvania | Jodi Maranchie |
| Virtual Histology of the Bladder Wall for Bladder Cancer Staging; A Novel Intravesical Contrast-Enha... NCT ID: NCT04369560 State: Pennsylvania Investigator/Sponsoring Organization: Jodi Maranchie |
Pennsylvania | Jodi Maranchie |
| Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial Carcin... NCT ID: NCT04501094 State: Maryland Investigator/Sponsoring Organization: National Cancer Institute (NCI) |
Maryland | National Cancer Institute (NCI) |
| Anti-PD-1 mAb Therapy Alone or With Metabolic Modulators to Reverse Tumor Hypoxia and Immune Dysfunc... NCT ID: NCT04114136 State: Pennsylvania Investigator/Sponsoring Organization: Dan Zandberg |
Pennsylvania | Dan Zandberg |
| Anti-PD-1 mAb Therapy Alone or With Metabolic Modulators to Reverse Tumor Hypoxia and Immune Dysfunc... NCT ID: NCT04114136 State: Pennsylvania Investigator/Sponsoring Organization: Dan Zandberg |
Pennsylvania | Dan Zandberg |
| Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial Carcin... NCT ID: NCT04501094 State: Maryland Investigator/Sponsoring Organization: National Cancer Institute (NCI) |
Maryland | National Cancer Institute (NCI) |
| Bintrafusp Alfa Monotherapy in Metastatic or Locally Advanced/Unresectable Urothelial Cancer With Di... NCT ID: NCT04349280 State: Multi-State Trial Investigator/Sponsoring Organization: GlaxoSmithKline |
Multi-State Trial | GlaxoSmithKline |
| Neoadjuvant AGEN1884 Plus AGEN2034 in Combination With Cisplatin-Gemcitabine for Muscle-Invasive Bla... NCT ID: NCT04430036 State: Texas Investigator/Sponsoring Organization: The University of Texas Health Science Center at San Antonio |
Texas | The University of Texas Health Science Center at San Antonio |
| PET Biodistribution Study of 68Ga-FAPI-46 in Patients With Different Malignancies: An Exploratory Bi... NCT ID: NCT04459273 State: California Investigator/Sponsoring Organization: Jonsson Comprehensive Cancer Center |
California | Jonsson Comprehensive Cancer Center |
| CRESTONE: Seribantumab in Adult Patients With Neuregulin-1 (NRG1) Fusion Positive Locally Advanced ... NCT ID: NCT04383210 State: Multi-State Trial Investigator/Sponsoring Organization: Elevation Oncology |
Multi-State Trial | Elevation Oncology |
| Behavioral Weight Loss for Overweight and Obese Cancer Survivors in Maryland: A Demonstration Projec... NCT ID: NCT04534309 State: Maryland Investigator/Sponsoring Organization: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Maryland | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
| Neoadjuvant AGEN1884 Plus AGEN2034 in Combination With Cisplatin-Gemcitabine for Muscle-Invasive Bla... NCT ID: NCT04430036 State: Texas Investigator/Sponsoring Organization: The University of Texas Health Science Center at San Antonio |
Texas | The University of Texas Health Science Center at San Antonio |
| CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients With Neuregulin-1 (NRG1) Fusion Positive... NCT ID: NCT04383210 State: Multi-State Trial Investigator/Sponsoring Organization: Elevation Oncology |
Multi-State Trial | Elevation Oncology |
| PET Biodistribution Study of 68Ga-FAPI-46 in Patients With Different Malignancies: An Exploratory Bi... NCT ID: NCT04459273 State: California Investigator/Sponsoring Organization: Jonsson Comprehensive Cancer Center |
California | Jonsson Comprehensive Cancer Center |
| Neoadjuvant AGEN1884 Plus AGEN2034 in Combination With Cisplatin-Gemcitabine for Muscle-Invasive Bla... NCT ID: NCT04430036 State: Texas Investigator/Sponsoring Organization: The University of Texas Health Science Center at San Antonio |
Texas | The University of Texas Health Science Center at San Antonio |
| Addressing Barriers to Palliative Care Use in Bladder Cancer Through Better Understanding of Knowled... NCT ID: NCT04598724 State: Florida Investigator/Sponsoring Organization: H. Lee Moffitt Cancer Center and Research Institute |
Florida | H. Lee Moffitt Cancer Center and Research Institute |
| CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With Muscle Invasive Bladder Cancer ... NCT ID: NCT04610671 State: Florida Investigator/Sponsoring Organization: H. Lee Moffitt Cancer Center and Research Institute |
Florida | H. Lee Moffitt Cancer Center and Research Institute |
| Biological and Clinical Activities of GEN-001 in Combination With Avelumab in Patients With Advanced... NCT ID: NCT04601402 State: Multi-State Trial Investigator/Sponsoring Organization: Genome & Company |
Multi-State Trial | Genome & Company |
| Pembrolizumab and Ramucirumab in Patients With Progressive Transitional Cell Carcinoma After Treatme... NCT ID: NCT04179110 State: Connecticut Investigator/Sponsoring Organization: Yale University |
Connecticut | Yale University |
| ICP-192 in Patients With Advanced Solid Tumors and FGFR Gene Alterations NCT ID: NCT04565275 State: Florida Investigator/Sponsoring Organization: Beijing InnoCare Pharma Tech Co., Ltd. |
Florida | Beijing InnoCare Pharma Tech Co., Ltd. |
| Pembrolizumab as Standard of Care + sEphB4-HSA in Chemotherapy Ineligible or Chemotherapy Refusing P... NCT ID: NCT04486781 State: California Investigator/Sponsoring Organization: Vasgene Therapeutics, Inc |
California | Vasgene Therapeutics, Inc |
| Immunoassay for Predicting Intravesical BCG Response in Patients With Intermediate or High-risk Non-... NCT ID: NCT04564781 State: California Investigator/Sponsoring Organization: Cedars-Sinai Medical Center |
California | Cedars-Sinai Medical Center |
| Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens ... NCT ID: NCT04596033 State: Tennessee Investigator/Sponsoring Organization: Genocea Biosciences, Inc. |
Tennessee | Genocea Biosciences, Inc. |
| GEMINI: Study of Intraoperative Gemcitabine Intravesical Instillation in Patients Undergoing Radical... NCT ID: NCT04398368 State: Multi-State Trial Investigator/Sponsoring Organization: Mayo Clinic |
Multi-State Trial | Mayo Clinic |
| Enhancement of Immune Reconstitution and Vaccine Responses With Administration of Recombinant Human ... NCT ID: NCT04054752 State: Maryland Investigator/Sponsoring Organization: National Cancer Institute (NCI) |
Maryland | National Cancer Institute (NCI) |
| Study of SBT6050 Alone and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors ... NCT ID: NCT04460456 State: Multi-State Trial Investigator/Sponsoring Organization: Silverback Therapeutics |
Multi-State Trial | Silverback Therapeutics |
| Sacituzumab Govitecan Versus Treatment of Physician's Choice in Subjects With Metastatic or Locally ... NCT ID: NCT04527991 State: Multi-State Trial Investigator/Sponsoring Organization: Immunomedics, Inc. |
Multi-State Trial | Immunomedics, Inc. |
| Sym021 (Anti-PD-1) in Combination With Either Sym022 (Anti-LAG-3) or Sym023 (Anti-TIM-3) in Patients... NCT ID: NCT04641871 State: Multi-State Trial Investigator/Sponsoring Organization: Symphogen A/S |
Multi-State Trial | Symphogen A/S |
| Sacituzumab Govitecan Versus Treatment of Physician's Choice in Subjects With Metastatic or Locally ... NCT ID: NCT04527991 State: Multi-State Trial Investigator/Sponsoring Organization: Immunomedics, Inc. |
Multi-State Trial | Immunomedics, Inc. |
| Sym021 (Anti-PD-1) in Combination With Either Sym022 (Anti-LAG-3) or Sym023 (Anti-TIM-3) in Patients... NCT ID: NCT04641871 State: Multi-State Trial Investigator/Sponsoring Organization: Symphogen A/S |
Multi-State Trial | Symphogen A/S |
| SQ3370 in Patients With Advanced Solid Tumors NCT ID: NCT04106492 State: Multi-State Trial Investigator/Sponsoring Organization: Shasqi, Inc. |
Multi-State Trial | Shasqi, Inc. |
| CG0070 Combined With Pembrolizumab in Patients With Non Muscle Invasive Bladder Cancer (NMIBC) Unres... NCT ID: NCT04387461 State: Multi-State Trial Investigator/Sponsoring Organization: CG Oncology, Inc. |
Multi-State Trial | CG Oncology, Inc. |
| CG0070 in Patients With Non-Muscular Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus-Calmet... NCT ID: NCT04452591 State: Multi-State Trial Investigator/Sponsoring Organization: CG Oncology, Inc. |
Multi-State Trial | CG Oncology, Inc. |
| CG0070 Combined With Pembrolizumab in Patients With Non Muscle Invasive Bladder Cancer (NMIBC) Unres... NCT ID: NCT04387461 State: Multi-State Trial Investigator/Sponsoring Organization: CG Oncology, Inc. |
Multi-State Trial | CG Oncology, Inc. |
| Feasibility Testing of Patient Reported Outcomes - Informed Symptom Management System (PRISMS) NCT ID: NCT04492007 State: North Carolina Investigator/Sponsoring Organization: UNC Lineberger Comprehensive Cancer Center |
North Carolina | UNC Lineberger Comprehensive Cancer Center |
| SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies NCT ID: NCT04254107 State: Multi-State Trial Investigator/Sponsoring Organization: Seagen Inc. |
Multi-State Trial | Seagen Inc. |
| Feasibility Testing of Patient Reported Outcomes - Informed Symptom Management System (PRISMS) NCT ID: NCT04492007 State: North Carolina Investigator/Sponsoring Organization: UNC Lineberger Comprehensive Cancer Center |
North Carolina | UNC Lineberger Comprehensive Cancer Center |
| CPX-POM in Patients With Newly Diagnosed or Recurrent Bladder Tumors NCT ID: NCT04525131 State: Kansas Investigator/Sponsoring Organization: CicloMed LLC |
Kansas | CicloMed LLC |
| Adenovirally Transduced Autologous Macrophages Engineered to Contain an Anti-HER2 Chimeric Antigen R... NCT ID: NCT04660929 State: Multi-State Trial Investigator/Sponsoring Organization: Carisma Therapeutics Inc |
Multi-State Trial | Carisma Therapeutics Inc |
| Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR T Cells in Patients Wit... NCT ID: NCT03740256 State: Texas Investigator/Sponsoring Organization: Baylor College of Medicine |
Texas | Baylor College of Medicine |
| TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Musc... NCT ID: NCT04658862 State: Multi-State Trial Investigator/Sponsoring Organization: Janssen Research & Development, LLC |
Multi-State Trial | Janssen Research & Development, LLC |
| Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer Patients NCT ID: NCT04604158 State: California Investigator/Sponsoring Organization: Gillian Gresham |
California | Gillian Gresham |
| UGN-102 With or Without TURBT in Patients With Low Grade Intermediate Risk Non-Muscle-Invasive Bladd... NCT ID: NCT04688931 State: Multi-State Trial Investigator/Sponsoring Organization: UroGen Pharma Ltd. |
Multi-State Trial | UroGen Pharma Ltd. |
| INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid T... NCT ID: NCT04580485 State: Texas Investigator/Sponsoring Organization: Incyte Corporation |
Texas | Incyte Corporation |
| INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid ... NCT ID: NCT04580485 State: Texas Investigator/Sponsoring Organization: Incyte Corporation |
Texas | Incyte Corporation |
| TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With High... NCT ID: NCT04640623 State: Multi-State Trial Investigator/Sponsoring Organization: Janssen Research & Development, LLC |
Multi-State Trial | Janssen Research & Development, LLC |
| Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unre... NCT ID: NCT04579380 State: California Investigator/Sponsoring Organization: Seagen Inc. |
California | Seagen Inc. |
| Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unre... NCT ID: NCT04579380 State: California Investigator/Sponsoring Organization: Seagen Inc. |
California | Seagen Inc. |
